Skip to main content

Table 2 Baseline patient characteristics

From: A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia

Patient characteristics n (%)
Age
 Median (years) 61
 Range (years) 29–82
Sex
 male/female 15 (63) / 9 (38)
Disease
 ALL 11 (46)
 BCP-ALL 10
 T-ALL 1
 AML 12 (50)
 CML-BP 1 (4)
 Extramedullary disease 5 (21)
 SCT prior to study therapy 16 (67)
 SCT in AML patients 6
 SCT in ALL patients 9
 SCT in CML-BP patient 1
  1. Baseline patient characteristics reveal a median age of 61 and mainly patients with BCP-ALL and AML, who previously in most cases underwent an allogeneic SCT